Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
GERN 
Geron Corporation (GERN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: GERN (1-star) is a SELL. SELL since 2 days. Simulated Profits (-9.59%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.62
1 Year Target Price $3.62
| 4 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.41% | Avg. Invested days 28 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 810.28M USD | Price to earnings Ratio - | 1Y Target Price 3.62 |
Price to earnings Ratio - | 1Y Target Price 3.62 | ||
Volume (30-day avg) 9 | Beta 0.63 | 52 Weeks Range 1.09 - 4.83 | Updated Date 09/14/2025 |
52 Weeks Range 1.09 - 4.83 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -53.52% | Operating Margin (TTM) -25.4% |
Management Effectiveness
Return on Assets (TTM) -9.63% | Return on Equity (TTM) -31.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 544143682 | Price to Sales(TTM) 4.93 |
Enterprise Value 544143682 | Price to Sales(TTM) 4.93 | ||
Enterprise Value to Revenue 3.31 | Enterprise Value to EBITDA -9.06 | Shares Outstanding 638017024 | Shares Floating 534077712 |
Shares Outstanding 638017024 | Shares Floating 534077712 | ||
Percent Insiders 0.09 | Percent Institutions 81.97 |
Upturn AI SWOT
Geron Corporation
Company Overview
History and Background
Geron Corporation was founded in 1990 and is a late-stage clinical biopharmaceutical company focused on the development and commercialization of therapeutics for hematologic malignancies. It pioneered the field of telomerase biology.
Core Business Areas
- Hematologic Malignancies: Focuses on the development of therapies for blood cancers.
Leadership and Structure
The leadership team consists of experienced professionals in drug development and commercialization. The company is structured around research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Imetelstat: Imetelstat is a telomerase inhibitor being developed for the treatment of myelodysplastic syndromes (MDS) and myelofibrosis (MF). Geron is seeking regulatory approval for Imetelstat in MDS. There is no market share data for the revenue as it has not been approved yet but it is predicted that if it gets approval for MDS, it will capture a sizeable portion of the market currently serviced by Revlimid (Celgene) and Vidaza (BMS) and generic equivalents, and Besremi from PharmaEssentia.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and rapidly evolving, with significant investment in research and development. The hematology market is driven by the need for novel treatments for blood cancers.
Positioning
Geron aims to be a leader in hematologic malignancies with Imetelstat, focusing on MDS and MF. Their competitive advantage lies in telomerase inhibition, targeting a novel mechanism of action.
Total Addressable Market (TAM)
The total addressable market for MDS and MF treatments is significant. Estimates suggest a multi-billion dollar market. Geron is positioned to capture a substantial portion of this market with successful Imetelstat approval.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (telomerase inhibition)
- Late-stage clinical development program
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on a single product (Imetelstat)
- Regulatory risk (approval not guaranteed)
- Commercialization risk (dependence on partners or building commercial infrastructure)
- History of clinical setbacks
Opportunities
- Expansion to other hematologic malignancies
- Partnerships for commercialization
- Positive clinical trial results
- First-in-class therapy
Threats
- Competition from existing therapies
- Failure to obtain regulatory approval
- Adverse safety events in clinical trials
- Patent challenges
Competitors and Market Share
Key Competitors
- Bayer AG (BAYRY)
- Bristol Myers Squibb (BMY)
- Novartis (NVS)
- PharmaEssentia (6446.TW)
Competitive Landscape
Geron's advantage lies in a potentially novel mechanism of action compared to existing treatments. Disadvantages include reliance on a single product and regulatory risk.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the pre-revenue stage of the company. Future growth is contingent on Imetelstat's approval and commercialization.
Future Projections: Analyst estimates project significant revenue growth following potential Imetelstat approval.
Recent Initiatives: Recent initiatives include completing the Phase 3 clinical trials for Imetelstat in MDS and preparing for regulatory submissions.
Summary
Geron is a late-stage biopharmaceutical company focused on hematologic malignancies. Imetelstat has the potential to be a significant treatment if approved. The company is reliant on the success of imetelstat. The clinical data will need to be very strong to compete with the market leaders BMY and NVS.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary. Future performance is not guaranteed.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Geron Corporation
Exchange NASDAQ | Headquaters Foster City, CA, United States | ||
IPO Launch date 1996-06-30 | CEO, President & Director Mr. Harout Semerjian | ||
Sector Healthcare | Industry Biotechnology | Full time employees 229 | Website https://www.geron.com |
Full time employees 229 | Website https://www.geron.com | ||
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.